よむ、つかう、まなぶ。
【参考資料6】抗微生物薬適正使用の手引き 第三版 補遺 (34 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
44. Hayakawa K, Matsumura Y, Uemura K. et al. Effectiveness of cefmetazole versus
meropenem for invasive urinary tract infections caused by extended-spectrum betalactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2023
Oct;67(10):e0051023.
45. UMIN-CTR ホームページ. at https://center6.umin.ac.jp/cgi-openbin/ctr/ctr_view.cgi?recptno=R000055809.)
46. Matsumura Y, Yamamoto M, Nagao M, Tanaka M, Takakura S, Ichiyama S. In vitro activities
and detection performances of cefmetazole and flomoxef for extended-spectrum betalactamase and plasmid-mediated AmpC beta-lactamase-producing Enterobacteriaceae.
Diagn Microbiol Infect Dis. 2016 Apr;84(4):322-327.
47. アンチバイオグラム作成ガイドライン, 感染症教育コンソーシアム, 2019. 2019. at
https://amr.ncgm.go.jp/pdf/201904_antibaiogram_guideline.pdf.)
48. Lee NY, Lee CC, Li CW. et al. Cefepime Therapy for Monomicrobial Enterobacter cloacae
Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible DoseDependent Isolates. Antimicrob Agents Chemother. 2015 Dec;59(12):7558-7563.
49. Coyne AJK, Ghali AE, Lucas K. et al. High-dose Cefepime vs Carbapenems for Bacteremia
Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC betalactamase Production. Open Forum Infect Dis. 2023 Jan;10(3):ofad034.
50. Hareza D, Simner PJ, Bergman Y, Jacobs E, Cosgrove SE, Tamma PD. The Frequency of
Extended-Spectrum beta-Lactamase Genes Harbored by Enterobacterales Isolates at High
Risk for Clinically Significant Chromosomal ampC Expression. Open Forum Infect Dis. 2023
Mar;10(4):ofad175.
51. Maan G, Keitoku K, Kimura N. et al. Cefepime-induced neurotoxicity: systematic review. J
Antimicrob Chemother. 2022 Oct;77(11):2908-2921.
52. Stewart AG, Paterson DL, Young B. et al. Meropenem Versus Piperacillin-Tazobactam for
Definitive Treatment of Bloodstream Infections Caused by AmpC beta-Lactamase-Producing
Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia
marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum
Infect Dis. 2021 Aug;8(8):ofab387.
53. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or
continuous versus short-term intravenous infusion of carbapenems and
piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013
Jan;56(2):272-282.
54. Tamma PD, Conley AT, Cosgrove SE. et al. Association of 30-Day Mortality With Oral StepDown vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae
Bacteremia. JAMA. Intern Med. 2019 Mar;179(3):316-323.
55. Punjabi C, Tien V, Meng L, Deresinski S, Holubar M. Oral Fluoroquinolone or Trimethoprimsulfamethoxazole vs. ss-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia:
Systematic Review and Meta-analysis. Open Forum Infect Dis. 2019 Aug;6(10):ofz364.
56. 抗菌薬 TDM 臨床実践ガイドライン 公益社団法人日本化学療法学会/一般社団法人日本 TDM
学会. 2022. at https://www.chemotherapy.or.jp/uploads/files/guideline/tdm2022.pdf.)
34
meropenem for invasive urinary tract infections caused by extended-spectrum betalactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2023
Oct;67(10):e0051023.
45. UMIN-CTR ホームページ. at https://center6.umin.ac.jp/cgi-openbin/ctr/ctr_view.cgi?recptno=R000055809.)
46. Matsumura Y, Yamamoto M, Nagao M, Tanaka M, Takakura S, Ichiyama S. In vitro activities
and detection performances of cefmetazole and flomoxef for extended-spectrum betalactamase and plasmid-mediated AmpC beta-lactamase-producing Enterobacteriaceae.
Diagn Microbiol Infect Dis. 2016 Apr;84(4):322-327.
47. アンチバイオグラム作成ガイドライン, 感染症教育コンソーシアム, 2019. 2019. at
https://amr.ncgm.go.jp/pdf/201904_antibaiogram_guideline.pdf.)
48. Lee NY, Lee CC, Li CW. et al. Cefepime Therapy for Monomicrobial Enterobacter cloacae
Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible DoseDependent Isolates. Antimicrob Agents Chemother. 2015 Dec;59(12):7558-7563.
49. Coyne AJK, Ghali AE, Lucas K. et al. High-dose Cefepime vs Carbapenems for Bacteremia
Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC betalactamase Production. Open Forum Infect Dis. 2023 Jan;10(3):ofad034.
50. Hareza D, Simner PJ, Bergman Y, Jacobs E, Cosgrove SE, Tamma PD. The Frequency of
Extended-Spectrum beta-Lactamase Genes Harbored by Enterobacterales Isolates at High
Risk for Clinically Significant Chromosomal ampC Expression. Open Forum Infect Dis. 2023
Mar;10(4):ofad175.
51. Maan G, Keitoku K, Kimura N. et al. Cefepime-induced neurotoxicity: systematic review. J
Antimicrob Chemother. 2022 Oct;77(11):2908-2921.
52. Stewart AG, Paterson DL, Young B. et al. Meropenem Versus Piperacillin-Tazobactam for
Definitive Treatment of Bloodstream Infections Caused by AmpC beta-Lactamase-Producing
Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia
marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum
Infect Dis. 2021 Aug;8(8):ofab387.
53. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or
continuous versus short-term intravenous infusion of carbapenems and
piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013
Jan;56(2):272-282.
54. Tamma PD, Conley AT, Cosgrove SE. et al. Association of 30-Day Mortality With Oral StepDown vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae
Bacteremia. JAMA. Intern Med. 2019 Mar;179(3):316-323.
55. Punjabi C, Tien V, Meng L, Deresinski S, Holubar M. Oral Fluoroquinolone or Trimethoprimsulfamethoxazole vs. ss-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia:
Systematic Review and Meta-analysis. Open Forum Infect Dis. 2019 Aug;6(10):ofz364.
56. 抗菌薬 TDM 臨床実践ガイドライン 公益社団法人日本化学療法学会/一般社団法人日本 TDM
学会. 2022. at https://www.chemotherapy.or.jp/uploads/files/guideline/tdm2022.pdf.)
34